Mabion has received a termination of the cooperation agreement from Mylan Ireland

–

—

Mabion received from Mylan Ireland the termination of the cooperation agreement from 2016 – the company said in a press release. The termination is effected with a 90-day notice period.

Under the 2016 agreement, Mabion granted the Mylan group the exclusive right to sell MabionCD20 in the European Union and the Balkan countries. As a result of the annex to the agreement concluded in April 2021, Mylan remained the company’s non-exclusive distribution partner for the drug in selected countries in such areas as, inter alia, Australia, New Zealand, Mexico, Central America, South Africa and Southeast Asia.

“The key rights to sell MabionCD20 in the territory of the European Union and the United States remained and remain the property of the Company and may be subject to commercialization in the future, depending on the needs and decisions of the company” – it was written in the release.

Mabion said that the termination of the contract does not currently entail the need for the company to make payments or additional financial obligations.

“The company informs that it currently has full and necessary flexibility in the commercialization of MabionCD20 on all markets, which may have a positive impact on the implementation of the strategic investor acquisition process” – it was written in the release.

MabionCD20 is the company’s key project. It is a biosimilar drug to MabThera / Rituxan (rituximab), a pharmaceutical owned by Roche. The clinical trial of the drug conducted by Mabion included patients with rheumatoid arthritis (RA) and lymphoma (NHL). (PAP Biznes)

sar / os /